A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity

The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regimen using a canarypox vector and an HIV envelope protein with alum, as shown in the RV144 trial. Since the efficacy was weak, and previous HIV vaccine trials designed to generate antibody responses fai...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Pattacini, Laura, Mize, Gregory J., Graham, Jessica B., Fluharty, Tayler R., Graham, Tisha M., Lingnau, Karen, Wizel, Benjamin, Perdiguero, Beatriz, Esteban, Mariano, Pantaleo, Giuseppe, Shen, Mingchao, Spies, Gregory A., McElrath, M. Juliana, Lund, Jennifer M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2012
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3405041/
https://ncbi.nlm.nih.gov/pubmed/22848738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0042163
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi